Enanta Pharmaceuticals (NASDAQ:ENTA) Lifted to Sell at BidaskClub

BidaskClub upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a strong sell rating to a sell rating in a research report report published on Saturday morning, BidAskClub reports.

ENTA has been the subject of a number of other research reports. Wolfe Research began coverage on shares of Enanta Pharmaceuticals in a research note on Friday, May 24th. They set an outperform rating and a $117.00 price target for the company. ValuEngine upgraded shares of Enanta Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Friday. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, August 12th. Finally, Berenberg Bank set a $130.00 price target on shares of Enanta Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $107.25.

Shares of Enanta Pharmaceuticals stock opened at $71.91 on Friday. The company has a fifty day simple moving average of $70.55 and a 200-day simple moving average of $84.78. Enanta Pharmaceuticals has a 12-month low of $63.37 and a 12-month high of $106.80. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of 20.66 and a beta of 0.97.



Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.27. Enanta Pharmaceuticals had a net margin of 29.22% and a return on equity of 15.16%. The business had revenue of $44.40 million during the quarter, compared to analysts’ expectations of $46.98 million. During the same quarter in the prior year, the business posted $0.97 EPS. The company’s revenue for the quarter was down 22.5% on a year-over-year basis. Analysts expect that Enanta Pharmaceuticals will post 2.47 earnings per share for the current year.

A number of large investors have recently modified their holdings of the stock. Mackenzie Financial Corp boosted its stake in Enanta Pharmaceuticals by 1,197.4% during the 2nd quarter. Mackenzie Financial Corp now owns 37,753 shares of the biotechnology company’s stock worth $3,186,000 after purchasing an additional 34,843 shares during the period. BlackRock Inc. raised its position in Enanta Pharmaceuticals by 1.5% during the 2nd quarter. BlackRock Inc. now owns 2,592,357 shares of the biotechnology company’s stock worth $218,743,000 after buying an additional 37,417 shares during the last quarter. Krensavage Asset Management LLC raised its position in Enanta Pharmaceuticals by 0.7% during the 2nd quarter. Krensavage Asset Management LLC now owns 479,576 shares of the biotechnology company’s stock worth $40,467,000 after buying an additional 3,534 shares during the last quarter. Verition Fund Management LLC purchased a new position in Enanta Pharmaceuticals during the 2nd quarter worth $229,000. Finally, ClariVest Asset Management LLC raised its position in Enanta Pharmaceuticals by 66.3% during the 2nd quarter. ClariVest Asset Management LLC now owns 52,939 shares of the biotechnology company’s stock worth $4,467,000 after buying an additional 21,096 shares during the last quarter. Hedge funds and other institutional investors own 88.57% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: What is the NASDAQ Stock Market?

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.